3 VC-Backed Biotechs Join Flurry Of Anticipated IPOs
Three venture capital-backed drugmakers lined up plans to tap the public market for a total of $195 million in capital, pushing the total number of life sciences companies to file for...To view the full article, register now.
Already a subscriber? Click here to view full article